International Development News
Development News Edition
Give Feedback
Cricket World Cup 2019

Health News Roundup: J&J baby powder probe; birth control exemptions blocked and more


Devdiscourse News Desk
Updated: 14-07-2019 19:00 IST
Health News Roundup: J&J baby powder probe; birth control exemptions blocked and more

Following is a summary of current health news briefs.

J&J faces U.S. criminal probe related to baby powder - Bloomberg

The U.S. Justice Department is pursuing a criminal probe into whether Johnson & Johnson lied about potential cancer risks of its talcum powder and has convened a grand jury in Washington, Bloomberg reported on Friday, citing people with knowledge of the matter. The Bloomberg report said the grand jury was looking into documents related to what company officials knew about any carcinogens in their products.

U.S. appeals court blocks Trump administration birth control exemptions

A federal appeals court on Friday blocked the Trump administration from enforcing new rules allowing employers to obtain exemptions from an Obamacare requirement they provide health insurance that covers women's birth control. The 3rd U.S. Circuit Court of Appeals in Philadelphia upheld a nationwide injunction that blocked the implementation of rules allowing employers with religious and moral objections to seek exemptions from the 2010 healthcare law's requirement.

Early risers may have lower breast cancer risk

Women who like to wake up early every day may be less likely to develop breast cancer than women who prefer to sleep in, a recent study suggests. While previous studies have linked inconsistent sleep schedules and getting too much rest to an increased risk of breast cancer, researchers haven't looked as often at how much women's wake-up time might impact this risk, researchers note in the BMJ.

Democrats take aim as Trump abandons drug pricing plan

Democrats see U.S. President Donald Trump becoming increasingly vulnerable to criticism about healthcare costs after the administration's decision to scrap a proposal to lower drug prices, and 2020 White House candidates are rushing to seize the spotlight on the issue. The debate over the future of the American healthcare system has become a focal point of the Democratic presidential nominating contest. As Trump has failed to make strides to remedy the problem, Democrats are becoming more vocal.

Cargill shuts animal-feed mills in China as fatal hog disease spreads

Cargill Inc shuttered animal-feed mills in China in recent months partly because the rapid spread of a fatal hog disease has reduced demand, a company executive said on Friday. The closures highlight the pain for global agriculture companies from the outbreak of African swine fever in China, the world's top hog producer and pork consumer.

U.S. federal judge orders FDA to implement 10-month deadline for e-cig applications

A U.S. federal judge on Friday ordered the Food and Drug Administration to impose a 10-month deadline for the submission of e-cigarette applications, turning the screws on companies like Juul Labs Inc whose products have come under intense scrutiny for their popularity among teenagers. The FDA last month proposed the shorter timeline after the U.S. District Court for Maryland ruled in a lawsuit filed by anti-tobacco groups that the agency had exceeded its authority in allowing e-cigarettes to remain on the market until 2022 before companies applied for regulatory approval.

Johnson & Johnson to test experimental HIV vaccine in U.S., Europe

Johnson & Johnson said on Friday it plans to conduct a late-stage study of its investigational vaccine for Human Immunodeficiency Virus (HIV) in several countries across the Americas and Europe, including the United States. The drugmaker already has a mid-stage HIV vaccine study underway in five southern African countries.

Eton's conjunctivitis treatment fails to win FDA nod; shares tumble

Eton Pharmaceuticals Inc said on Friday that the U.S. Food and Drug Administration declined to approve its treatment for conjunctivitis, sending its shares tumbling nearly 20 percent in extended trading. No concerns were raised about the clinical data in the application, and the company expects to respond to the FDA's complete response letter shortly, Eton said, without providing more detail.

Indivior loses appeal to block generic Suboxone opioid treatments

A divided federal appeals court on Friday ruled against Indivior Plc in its bid to stop Dr. Reddy's Laboratories Ltd and Alvogen from selling generic versions of its opioid addiction treatment Suboxone film that infringed its patents. The U.S. Federal Circuit Court of Appeals in Washington, which oversees many intellectual property cases, upheld lower court rulings that Dr. Reddy's did not infringe two Indivior patents related to Suboxone, and Alvogen did not infringe one of those patents.

(With inputs from agencies.)


POST A COMMENT